|drug665||COVID-19 positive via testing Wiki||1.00|
|D003141||Communicable Diseases NIH||0.08|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The objective of this study is to evaluate the efficacy and safety of 5131A for hospitalized patients of COVID-19.
Description: The percent of participants reduced by 2 points or moreMeasure: Ordinal scale outcome Time: 7, 14, 21, 28 days
Description: The percents of negative patients for COVID-19 virusMeasure: Viral negative Time: 1, 3, 5, 7, 10 days
Description: The change of NEWS from baselineMeasure: Change in NEWS Time: 7, 14, 21, 28 days
Description: The percent of participantsMeasure: mortality Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports